VivoSeq
Oncology

Metastatic Melanoma

324

Pipeline Programs↗

42

Active Trials↗

88

Companies Involved↗

Metastatic Melanoma is a highly competitive landscape with 324 programs across 88 companies. The most active players are Takeda, Nektar Therapeutics, Shanghai Juncell Therapeutics. 8 therapies are approved with 25 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

87/100

Pipeline Velocity

27/100

Mech. Concentration

4/100

Completion Rate

68/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

2 programs

Phase 1N

Nektar Therapeutics

2 programs

Phase 1S

Shanghai Juncell Therapeutics

2 programs

Phase 1P

Pain Therapeutics

1 program

Phase 1V

Valerio Therapeutics

1 program

Phase 1P

Provectus Biopharmaceuticals, Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

69%

Small molecule

211 of 306 classified programs — the dominant modality here.

31%ALL OTHERSMonoclonal antibody3210%Vaccine217%Protein / enzyme176%Cell therapy176%Peptide62%RNA therapy1<1%Other1<1%

Small molecule leads; the ring shows all 306 classified programs, each share of the total. Modality classified for 100% of 387 pipeline programs.

Analysis

Trial Status

426

clinical trials

Completed233 · 55%
Terminated82 · 19%
Unknown status39 · 9%
Withdrawn25 · 6%
Recruiting20 · 5%
Active, not recruiting18 · 4%
Other9 · 2%

Clinical Trials

Trial Activity

426 trials

Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia
Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07422779·100 enrolled
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT02621021·170 enrolled
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Recruiting·CCanadian Cancer Trials Group·Phase 3·NCT02821013·614 enrolled
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Recruiting·—·Phase 2·NCT03646617·54 enrolled
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
Recruiting·AAivita Biomedical, Inc.·Phase 1·NCT03743298·20 enrolled
Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07407166·40 enrolled
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
Recruiting·WWashington University School of Medicine·Phase 1·NCT05629546·33 enrolled
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Recruiting·SSheba Medical Center·Phase 2·NCT03166397·30 enrolled
Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma
Recruiting·—·N/A·NCT07223411·20 enrolled
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
Recruiting·—·Phase 1·NCT06783270·10 enrolled
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Recruiting·—·Phase 1·NCT06204991·10 enrolled
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Recruiting·AAlpha-9 Oncology USA Inc.·Phase 1·NCT07076550·50 enrolled
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
Recruiting·—·Phase 1·NCT04903119·30 enrolled
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05026983·35 enrolled
A Phase Ib Study of PRJ1-3024 for Treatment of Advanced or Metastatic Melanoma
Recruiting·ZZhuhai Yufan Biotechnologies Co., Ltd·Phase 1/2·NCT06727630·40 enrolled
Page 1 of 29

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)